
Mersana Therapeutics (NASDAQ:MRSN) brought in sales totaling $11.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 7.72%, resulting in a loss of $48.98 million. Mersana Therapeutics collected $11.00 thousand in revenue during Q3, but reported earnings showed a $45.47 million loss.